# Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

> **NCT03501979** · PHASE2 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Leptomeningeal Disease

## Interventions

- **DRUG:** Tucatinib
- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03501979
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-20
- **Primary completion:** 2021-06-22
- **Final completion:** 2021-06-22
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Study accrual ended early due to the FDA approval of tucatinib in metastatic HER2+ breast cancer
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03501979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03501979, "Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03501979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*